Cargando…

MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases

PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Claessens, Daniela, Ichhpujani, Parul, Singh, Rohan Bir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380298/
https://www.ncbi.nlm.nih.gov/pubmed/34420124
http://dx.doi.org/10.1007/s10792-021-02017-3
_version_ 1783741170133762048
author Claessens, Daniela
Ichhpujani, Parul
Singh, Rohan Bir
author_facet Claessens, Daniela
Ichhpujani, Parul
Singh, Rohan Bir
author_sort Claessens, Daniela
collection PubMed
description PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usability of a new smartphone-based testing method to assess metamorphopsia was evaluated in 45 patients experiencing metamorphopsia in at least one eye using the questionnaire “System Usability Score (SUS).” Additionally, the diagnostic adherence of self-monitoring with the Amsler grid was compared to self-monitoring with the novel software MacuFix®. RESULTS: The average score of the SUS questionnaire in this study was 76.7 ± 15.5, corresponding to the “good” score on the grading scale. The average interval between two home administered tests was significantly shorter (6 days) when the application was used as compared to using the Amsler grid (19 days). The odds ratio of the frequency of patients using the application to the patients using the home test was 4. CONCLUSION: MacuFix® application can help in effective home monitoring of macular function as high user satisfaction and increased testing frequency was observed in its use in patients with macular diseases.
format Online
Article
Text
id pubmed-8380298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-83802982021-08-23 MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases Claessens, Daniela Ichhpujani, Parul Singh, Rohan Bir Int Ophthalmol Original Paper PURPOSE: Macular diseases often lead to metamorphopsia, which is traditionally tested using the Amsler grid. This study evaluates a novel method for assessing metamorphopsia, based on the software AMD-A Metamorphopsia Detector, application MacuFix®. METHODS: In this observational study, the usability of a new smartphone-based testing method to assess metamorphopsia was evaluated in 45 patients experiencing metamorphopsia in at least one eye using the questionnaire “System Usability Score (SUS).” Additionally, the diagnostic adherence of self-monitoring with the Amsler grid was compared to self-monitoring with the novel software MacuFix®. RESULTS: The average score of the SUS questionnaire in this study was 76.7 ± 15.5, corresponding to the “good” score on the grading scale. The average interval between two home administered tests was significantly shorter (6 days) when the application was used as compared to using the Amsler grid (19 days). The odds ratio of the frequency of patients using the application to the patients using the home test was 4. CONCLUSION: MacuFix® application can help in effective home monitoring of macular function as high user satisfaction and increased testing frequency was observed in its use in patients with macular diseases. Springer Netherlands 2021-08-22 2022 /pmc/articles/PMC8380298/ /pubmed/34420124 http://dx.doi.org/10.1007/s10792-021-02017-3 Text en © The Author(s), under exclusive licence to Springer Nature B.V. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Claessens, Daniela
Ichhpujani, Parul
Singh, Rohan Bir
MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title_full MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title_fullStr MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title_full_unstemmed MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title_short MacuFix® versus Amsler grid for metamorphopsia categorization for macular diseases
title_sort macufix® versus amsler grid for metamorphopsia categorization for macular diseases
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380298/
https://www.ncbi.nlm.nih.gov/pubmed/34420124
http://dx.doi.org/10.1007/s10792-021-02017-3
work_keys_str_mv AT claessensdaniela macufixversusamslergridformetamorphopsiacategorizationformaculardiseases
AT ichhpujaniparul macufixversusamslergridformetamorphopsiacategorizationformaculardiseases
AT singhrohanbir macufixversusamslergridformetamorphopsiacategorizationformaculardiseases